1. Median Tumor Development Time
Supplementary Figure 1 a b
A20 Lymphoma
Lenalidomide: 5 or 50 mg/kg i.p.
for 35 consecutive days
DNA vaccination (50 ug/mouse)
Day 1 14 28 35 42
a continuous schedule for 35 consecutive days
A20 Lymphoma
Lenalidomide: 5 or 50 mg/kg i.p.
DNA vaccination (50 ug/mouse)
Day 4 14 28 35 42 7 18 21 32
an intermittent schedule c
Group#
Treatment
No. of mice
Median Tumor Development Time 1
50 mg pMCP3-sFv + Lenalidomide 5mg/kg for 35 consecutive days 10 33 2
50 mg pMCP3-sFv + Lenalidomide 50mg/kg for 35 consecutive days 25 3
50 mg pMCP3-sFv + Lenalidomide 5mg/kg intermittently
(Days 4,7,18,21,32, 35) 30 4
50 mg pMCP3-sFv + Lenalidomide 50mg/kg intermittently
(Days 4,7,18,21,32,35) 5
50 mg pMCP3-sFv alone
26.5 6
PBS
23.5

2. Supplementary Figure 2

3. Supplementary Figure 3 Naïve mice A20-challenged mice No treatment
Naïve mice
A20-challenged mice
No treatment
Lenalidomide
Cyclophosphamide
MDSC
Mean
1.57
11.47
1.39
8.26 SE
0.34
1.07
0.05
1.35
Treg
18.15
31.05
17.59
20.39
0.58
1.49
0.62
1.13 NK
8.53
6.60
8.54
4.21
0.40
0.51
0.29